ADX48621, a novel mGlu5 negative allosteric modulator alleviates L-DOPA-induced chorea and dystonia in the MPTP-lesioned macaque model of Parkinson's disease

被引：0
|
作者：
Hill, M. P.
Girard, F.
Keywood, C.
Poli, S. -M.
Crossman, A. R.
Ravenscroft, P.
Li, Q.
Bezard, E.
Mutel, V.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
295
引用
收藏
页码：S281 / S282
页数：2
相关论文
共 32 条
  • [1] ADX48621, an MGluR5 negative allosteric modulator alleviates L-DOPA-induced chorea and dystonia in the MPTP-lesioned macaque model of Parkinson's disease
    Keywood, C.
    Hill, M.
    Girard, F.
    Bezard, E.
    Poli, S.
    Mutel, V.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 96 - 96
  • [2] COMT inhibition as an approach to minimising L-DOPA-induced dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease
    Johnston, T. H.
    Huot, P.
    Koprich, J. B.
    Snoeren, T.
    Hill, M. P.
    Fox, S. H.
    Brotchie, J. M.
    [J]. MOVEMENT DISORDERS, 2013, 28 : S358 - S359
  • [3] L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease
    Huot, Philippe
    Johnston, Tom H.
    Koprich, James B.
    Fox, Susan H.
    Brotchie, Jonathan M.
    [J]. NEUROPHARMACOLOGY, 2012, 63 (05) : 829 - 836
  • [4] Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease
    Gomez-Ramirez, Jordi
    Johnston, Tom H.
    Visanji, Naomi P.
    Fox, Susan H.
    Brotchie, Jonathan M.
    [J]. MOVEMENT DISORDERS, 2006, 21 (06) : 839 - 846
  • [5] Potential anxiolytic- and antidepressant-like activity of Dipraglurant (ADX48621), the novel negative allosteric modulator (NAM) of the metabotropic glutamate 5 (mGlu5) receptor
    Podkowa, Karolina
    Palucha-Poniewiera, Agnieszka
    Poli, Sonia
    Pilc, Andrzej
    [J]. PHARMACOLOGICAL REPORTS, 2015, 67 : 34 - 35
  • [6] Seletracetam (UCB 44212) reduces L-dopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
    Michel, A
    Ravenscroft, P
    Hill, MP
    Bezard, E
    Crossman, AR
    Klitgaard, H
    [J]. MOVEMENT DISORDERS, 2005, 20 : S102 - S102
  • [7] The histamine H2 receptor antagonist, famotidine, reduces L-dopa-induced motor complications in the MPTP-lesioned macaque model of Parkinson's disease
    Fox, S. H.
    Johnston, T. H.
    Vandermeij, A.
    Brotchie, J. M.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S351 - S352
  • [8] FP0011 extends the duration of the anti-parkinsonian actions of L-DOPA and reduces L-DOPA-induced dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease
    Brotchie, J. M.
    Johnston, T. H.
    Fox, S. H.
    Zerr, P.
    Tiberghien, F.
    Bossi, L.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S95 - S95
  • [9] Selective Metabotropic Glutamate Receptor 5 (mGlu5) Antagonism Reduces L-DOPA-Induced Dyskinesia in MPTP-Lesioned Primates at the Expense of Anti-Parkinsonian Benefit
    Johnston, Tom H.
    Fox, Susan H.
    Piggott, Matthew J.
    Brotchie, Jonathan M.
    [J]. NEUROLOGY, 2010, 74 (09) : A84 - A84
  • [10] Reduction of L-DOPA-induced dyskinesia by α2-adrenergic receptor antagonists in the MPTP-lesioned marmoset model of Parkinson's disease.
    Henry, B
    Fox, SH
    Peggs, D
    Crossman, AR
    Brotchie, JM
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 198 - 198
1234